Titlebook: Resistance to Targeted Therapies in Lymphomas; Ana C. Xavier,Mitchell S. Cairo Book 2019 Springer Nature Switzerland AG 2019 lymphoma.hodg

山羊

Book 2019gation in the field of lymphoma therapy. The discussion will not only be on the understanding of the mechanisms of action or clinical response of those agents, but will also help the reader to understand the nature of lymphoma biology in patients who relapse or are refractor after exposure to those

字谜游戏

2196-5501 ing of the mechanisms of action or clinical response of those agents, but will also help the reader to understand the nature of lymphoma biology in patients who relapse or are refractor after exposure to those 978-3-030-24426-2978-3-030-24424-8Series ISSN 2196-5501 Series E-ISSN 2196-551X

庇护

个阿姨勾引你

裤子

Resistance to Chimeric Antigen Receptor T-Cell Therapy,ressive B-cell lymphomas. However, relapses post CAR-T cell therapy are common. In this chapter, we will discuss what is currently known about mechanisms of resistance to CAR-T cell therapy in B-cell lymphomas or leukemias.

GREEN

Resistance to Monoclonal Antibody Therapeutics in Lymphoma,ly to attempt to overcome or circumvent resistance to monoclonal antibody therapies in order to enhance treatment responses or improve survival at the time of relapse following monoclonal antibody based therapy.

暗讽

Resistance to Antibody-Drug Conjugate,acquired by the host environment and can developed against each of the individual components of the ADC. Given the rational design of ADCs, there is the ability to modify each of the components to develop improved agents that can overcome resistance.

无法解释

Mechanisms of Glucocorticoid Response and Resistance in Lymphoid Malignancies,cts to induce apoptosis in cells of the lymphoid lineage. Despite their clinical utility, . and acquired resistance to GC is a significant clinical problem that contributes to inferior outcomes for many of these diseases. This review summarizes what is currently known about mechanisms of GC resistan

mendacity

Resistance to Monoclonal Antibody Therapeutics in Lymphoma, and anaplastic large cell lymphoma, monoclonal antibody-based therapies are commonly utilized for the treatment of many lymphomas. Following decades of experience with rituximab, much has been learned about the mechanisms of action and potential mechanisms of resistance to monoclonal antibody thera

来这真柔软